An observational study in Multiple Sclerosis, sponsored by Region Gävleborg. Recruiting at 1 site in Sweden. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-02.
Sponsored by Region Gävleborg · Observational
Among 91 studies in Multiple Sclerosis with a site in Sweden — 10 open to participants now, 19 under way, 6 of them phase 3. Multiple Sclerosis · Sweden.
Among the 91 studies in Multiple Sclerosis with a site in Sweden, this one is the 15th largest by planned enrollment of the 16 observational ones, is one of 5 that started in 2025, is one of 16 observational ones, reaches primary completion later than 15 of the 18 other live ones, and was the 85th registered.
3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.
This study's planned enrollment of 20 is below the median of 100 across 970 observational studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →10 of the 91 studies in Multiple Sclerosis with a site in Sweden are open now, in 12 countries. Each count lists the studies.
Of the 430 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 211 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →91 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2025.
Median enrollment 278 across the 75 interventional studies, 179 across the 16 observational. Of the 70 that completed or were terminated, 41 (59%) have results posted.
63 of 91 have an industry lead sponsor. The 10 most frequent:
Region Gävleborg is the lead sponsor of 14 studies on the registry; 4 are open to participants now.
Region Gävleborg has 2 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Multiple Sclerosis with a site in Sweden that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03477500Phase 3Haukeland University HospitalRandomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS) | 2026-11-21 |
| NCT07211516Region GävleborgRelationship Between Cognition, Workforce Participation and Well-Being in Individuals With Multiple Sclerosis | 2026-11 |
| NCT07131553Karolinska InstitutetEvaluation of the Wheelchair School (Drivkraft) a Clinical Study | 2027-02-01 |
| NCT05901259Otto Bock Healthcare Products GmbHThe EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes | 2027-08-01 |
| NCT07149662Region StockholmImmune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy | 2027-10 |
Among the 91 studies in Multiple Sclerosis with a site in Sweden, from their registry updates:
Multiple sclerosis (MS) is a chronic neurodegenerative disease and a leading cause of reduced workforce participation due to neurological illness in Western countries. Over the past 30 years, new treatments have reduced symptom burden, allowing patients to stay in the workforce longer. However, fatigue and cognitive impairments remain major barriers to work capacity. This project aims to preliminary examine the impact of cognitive function on work ability, and assess the role of neuropsychologists in multidisciplinary rehabilitation teams. It consists of a feasibility study evaluating the integration of neuropsychological interventions into teambased work-oriented rehabilitation. The specific research questions are:
Our findings aim to enhance work-oriented rehabilitation and provide a deeper understanding of how to support individuals with MS in maintaining employment and overall well-being
Patients of working age with MS in Region Gävleborg who are refered for a neuropsychological assessment and who are not suffering from other diagnosis which impact their work ability to a large extent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Multiple sclerosis Age between 18-65 Refered to neuropsychological assessment at the Neurology departement at Gävle Hospital -
Exclusion Criteria:
Other diagnosis hindering work participation more than MS
-
Patients with MS and of working age (18-65) referred to neuropsychological evaluation.
Work participation
Percentage of full-time work. 100 % full-time work and 0% is not working at all.
Time frame: From baseline to 2-year follow-up
Hospital anxiety and depression scale
Self-assessment of anxiety and depression. Consists of two scales measuring the probability of having anxiety and depression respectively. Min score 0, max 21 for each scale. Higher scores indicate higher probability of anxiety/depression.
Time frame: From baseline to 2-year follow-up
WHO-5 Well-Being Index
Overall rating of well-being. The WHO-5 score range is a raw score of 0-25, which is then multiplied by 4 to get a percentage score of 0-100. Higher score indicates higher well-being.
Time frame: From baseline to 2-year follow-up
Brief index of job satisfaction
The Brief Index of Affective Job Satisfaction (BIAJS) has a score range of 1 to 5 for each of its four items, based on a 5-point Likert scale where 1 is "strongly disagree" and 5 is "strongly agree". The total BIAJS score is the sum of these four items, resulting in a possible range from 4 to 20, with higher scores indicating greater affective job satisfaction.
Time frame: From baseline to 2-year follow-up
Quantative work demands
Questions from the subscale "Quantitative demands" of the Copenhagen Psychosocial Questionnaire (COPSOQ-III) related to the demands of work. The COPSOQ-III uses Likert-like scales, and its items are coded with values of 0, 25, 50, 75, and 100 to achieve a 0-100 scale. Higher scores indicate more demands.
Time frame: From baseline to 2-year follow-up
Can-Work-S
Three questions from a questionnaire developed to measure work-life balance after cancer. Each item ranges from 1 to 5 with higher scores indicating worse work-life balance.
Time frame: From baseline to 2-year follow-up
Plan to share: No — To comply with the conditions set by the ethical review board, individual participant data (IPD) cannot be shared with other researchers. However, aggregated data are available upon reasonable reques
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Sep 2028, 38 months after the start.
Of 334 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 73. This study's planned 38 months is close to that.
Counting every sponsor, half of 425 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Region Gävleborg